Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhib...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2022-05-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/524013 |
| _version_ | 1811251048796389376 |
|---|---|
| author | Yumi Kambayashi Kentaro Ohuchi Hiromu Chiba Erika Tamabuchi Tasuku Nagasawa Yoshihide Asano Taku Fujimura |
| author_facet | Yumi Kambayashi Kentaro Ohuchi Hiromu Chiba Erika Tamabuchi Tasuku Nagasawa Yoshihide Asano Taku Fujimura |
| author_sort | Yumi Kambayashi |
| collection | DOAJ |
| description | Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented. |
| first_indexed | 2024-04-12T16:13:42Z |
| format | Article |
| id | doaj.art-890e413afd62412f9aa1a9a8dfb0f73e |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-12T16:13:42Z |
| publishDate | 2022-05-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-890e413afd62412f9aa1a9a8dfb0f73e2022-12-22T03:25:48ZengKarger PublishersCase Reports in Oncology1662-65752022-05-0115246947210.1159/000524013524013Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination TherapyYumi Kambayashi0Kentaro Ohuchi1Hiromu Chiba2Erika Tamabuchi3Tasuku Nagasawa4Yoshihide Asano5Taku Fujimura6Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, JapanDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, JapanDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, JapanDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, JapanDivision of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University Hospital, Sendai, JapanDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, JapanDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, JapanEncorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented.https://www.karger.com/Article/FullText/524013tubulointerstitial nephritisbraf/mek inhibitoradverse eventrheumatoid arthritismelanoma |
| spellingShingle | Yumi Kambayashi Kentaro Ohuchi Hiromu Chiba Erika Tamabuchi Tasuku Nagasawa Yoshihide Asano Taku Fujimura Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy Case Reports in Oncology tubulointerstitial nephritis braf/mek inhibitor adverse event rheumatoid arthritis melanoma |
| title | Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy |
| title_full | Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy |
| title_fullStr | Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy |
| title_full_unstemmed | Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy |
| title_short | Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy |
| title_sort | tubulointerstitial nephritis in an advanced melanoma patient treated with encorafenib plus binimetinib combination therapy |
| topic | tubulointerstitial nephritis braf/mek inhibitor adverse event rheumatoid arthritis melanoma |
| url | https://www.karger.com/Article/FullText/524013 |
| work_keys_str_mv | AT yumikambayashi tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy AT kentaroohuchi tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy AT hiromuchiba tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy AT erikatamabuchi tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy AT tasukunagasawa tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy AT yoshihideasano tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy AT takufujimura tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy |